Acetylcholinesterase-inhibiting alkaloid · Fact sheet

Huperzine A

Also known as HupA

Huperzine A is a plant-derived acetylcholinesterase inhibitor studied for dementia. A U.S. trial did not meet its primary cognitive endpoint; a higher-dose secondary signal did not show clear improvement in daily function.

Not FDA approvedEarly human evidence

Brain, mood & sleep Specific conditions

What is Huperzine A?

Acetylcholinesterase breaks down acetylcholine. Inhibiting it changes cholinergic signaling and can produce drug-like effects.

Huperzia plant extracts and purified huperzine A are not equivalent formulations.

Benefits & claims

Interest in Huperzine A spans cognition and sleep, specific medical conditions. Study findings apply to the named formulation and population.

What the evidence supports

The 400-microgram arm showed a secondary cognitive signal at 11 weeks but not a conventionally significant result at 16 weeks.
Global clinical impression and daily-living outcomes were not significantly improved.
These data do not establish dementia prevention or reliable healthy-person memory enhancement.

Research areas

Formulation-specific human outcomes
Mechanistic research

Dosage & frequency

Human study context

This is an exposure from a named human study, not a generally established treatment or enhancement regimen.

U.S. huperzine A phase 2 trial

210 participants with mild to moderate Alzheimer disease

Amount: 200 or 400 micrograms per administration in separate groups
Frequency: Twice daily; primary efficacy assessment at week 16
Route studied or labeled: Oral

These are distinct dose arms. Micrograms are not milligrams. The primary 200-microgram comparison was negative, and this summary omits protocol escalation details.

A phase II trial of huperzine A in mild to moderate Alzheimer disease.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Identity and pharmacology: Acetylcholinesterase breaks down acetylcholine. Inhibiting it changes cholinergic signaling and can produce drug-like effects.
A phase II trial of huperzine A in mild to moderate Alzheimer disease. [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial].

Formulation differences

Huperzia plant extracts and purified huperzine A are not equivalent formulations.

Interactions & precautions

The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.

What is still unresolved

Reproducibility in larger independent trials
Long-term outcomes and adverse effects
Equivalence of different preparations and interaction profiles

A phase II trial of huperzine A in mild to moderate Alzheimer disease. [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial]. FDA: what approval means for supplements

Side effects & risks

Cholinergic pharmacology creates interaction concerns with other medicines affecting acetylcholine.
Short trials cannot establish long-term neurologic, cardiac or gastrointestinal safety across supplement formulations.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Early human evidence

The 210-person phase 2 trial tested separate 200 and 400 microgram twice-daily arms. The prespecified primary comparison at 200 micrograms was negative.

Studies

A phase II trial of huperzine A in mild to moderate Alzheimer disease.

210-person phase 2 study; primary endpoint negative.

[Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial].

Separate regional randomized Alzheimer trial.

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

No attributable personal accounts were found in the sources reviewed.

Approval status

No FDA-approved Huperzine A drug indication is established for the supplement uses discussed here. Supplement availability is not FDA approval of efficacy or safety.

No FDA-approved product for this entry

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

Reproducibility in larger independent trials
Long-term outcomes and adverse effects
Equivalence of different preparations and interaction profiles

Summary

These data do not establish dementia prevention or reliable healthy-person memory enhancement.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

pubmedA phase II trial of huperzine A in mild to moderate Alzheimer disease.
210-person phase 2 study; primary endpoint negative.
pubmed[Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial].
Separate regional randomized Alzheimer trial.
fdaFDA: what approval means for supplements
Dietary supplements are not approved by FDA for safety and effectiveness before marketing.

How we assess sources · Suggest a correction